Illustrative image.
Enhertu
Trastuzumab Deruxtecan
$2800.00
100mg/5mL · 1 vial
BrandBranded medicine· By AstraZeneca
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningInterstitial lung disease and embryo-fetal toxicity
Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms.
Embryo-Fetal Toxicity: Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
Interstitial lung disease (ILD) and pneumonitis, including severe, life threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
About Enhertu
Overview
Enhertu (trastuzumab deruxtecan) is a prescription cancer medicine supplied in a vial for preparation and infusion into a vein. It treats certain breast cancers in adults, including HER2-positive early or advanced disease and HER2-low or HER2-ultralow advanced disease, depending on test results and previous treatment. It also treats selected advanced HER2-mutant non-small cell lung cancers, HER2-positive stomach or gastroesophageal junction cancers, and other HER2-positive solid tumors after previous treatment. It works by attaching to HER2 on tumor cells and releasing a medicine inside them that damages DNA and causes cell death.
What it treats
HER2-positive early breast cancer in adults: before surgery for Stage II or III disease, followed by taxane, trastuzumab and pertuzumab treatment; or after surgery when invasive cancer remains following trastuzumab and taxane-based treatment before surgery. HER2-positive breast cancer that cannot be surgically removed or has spread: with pertuzumab as first-line treatment, or alone after specified prior HER2-directed treatment. HER2-low or HER2-ultralow breast cancer that cannot be surgically removed or has spread: alone for hormone receptor-positive disease that has progressed on endocrine therapy for metastatic disease. Also used alone for HER2-low disease after chemotherapy for metastatic disease, or when cancer returns during or within six months of completing chemotherapy given after surgery. Non-small cell lung cancer that cannot be surgically removed or has spread and has an activating HER2 mutation: alone after prior systemic therapy. HER2-positive gastric or gastroesophageal junction adenocarcinoma that is locally advanced or has spread: alone after prior trastuzumab-based treatment. HER2-positive (IHC 3+) solid tumors that cannot be surgically removed or have spread: alone after prior systemic treatment when there are no satisfactory alternative treatments. All uses are for adults. The lung cancer and solid tumor indications have accelerated approval based on tumor response and how long it lasts; continued approval may depend on confirmatory trials verifying clinical benefit.
Safety information
Side effects
Common side effects include nausea, vomiting, diarrhea, constipation, tiredness, hair loss, reduced appetite, and muscle or joint pain. Blood tests may show reduced red or white blood cells, reduced platelets, low potassium, or increased liver enzymes. Side effects vary by the cancer being treated and whether Enhertu is used with pertuzumab. Other common effects in some groups include peripheral nerve problems, rash, mouth inflammation, fever, respiratory infections, abdominal pain, weight loss, and increased bilirubin. Serious side effects that warrant contacting a doctor include lung inflammation (interstitial lung disease or pneumonitis), low neutrophils, a type of white blood cell, and reduced heart pumping function, including congestive heart failure. Blood counts and heart function need monitoring before and during treatment. These problems may require treatment to be interrupted, reduced or stopped by the treating clinician. Enhertu must be permanently stopped if symptomatic congestive heart failure develops.
FDA boxed warning
Interstitial lung disease and embryo-fetal toxicity
Interstitial Lung Disease (ILD) and pneumonitis, including severe, life-threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms.
Embryo-Fetal Toxicity: Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
Interstitial lung disease (ILD) and pneumonitis, including severe, life threatening, and fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The FDA label lists no contraindications for Enhertu. However, it includes precautions for low neutrophil counts (neutropenia) and reduced heart pumping function. Complete blood counts should be checked before treatment, before each dose and as clinically indicated. Neutropenia may require treatment interruption or dose reduction by the prescriber. Heart pumping function should be assessed before treatment and at regular intervals during treatment as clinically indicated. Reduced heart function may require treatment interruption or discontinuation. Enhertu must be permanently stopped in patients with symptomatic congestive heart failure. Pregnancy status should be verified before starting treatment in females who could become pregnant. Do not breastfeed during treatment.
Using Enhertu
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [DAIICHI SANKYO INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00